Compass Therapeutics (CMPX) Research & Development (2023 - 2025)
Historic Research & Development for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to $12.8 million.
- Compass Therapeutics' Research & Development rose 4893.17% to $12.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.3 million, marking a year-over-year increase of 3258.49%. This contributed to the annual value of $42.3 million for FY2024, which is 1107.56% up from last year.
- Latest data reveals that Compass Therapeutics reported Research & Development of $12.8 million as of Q3 2025, which was up 4893.17% from $16.4 million recorded in Q2 2025.
- In the past 5 years, Compass Therapeutics' Research & Development registered a high of $16.4 million during Q2 2025, and its lowest value of $6.6 million during Q1 2023.
- For the 3-year period, Compass Therapeutics' Research & Development averaged around $11.2 million, with its median value being $11.2 million (2024).
- As far as peak fluctuations go, Compass Therapeutics' Research & Development crashed by 247.99% in 2024, and later skyrocketed by 4893.17% in 2025.
- Compass Therapeutics' Research & Development (Quarter) stood at $12.4 million in 2023, then grew by 4.93% to $13.0 million in 2024, then fell by 1.63% to $12.8 million in 2025.
- Its last three reported values are $12.8 million in Q3 2025, $16.4 million for Q2 2025, and $13.1 million during Q1 2025.